JP2017530947A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530947A5 JP2017530947A5 JP2017509632A JP2017509632A JP2017530947A5 JP 2017530947 A5 JP2017530947 A5 JP 2017530947A5 JP 2017509632 A JP2017509632 A JP 2017509632A JP 2017509632 A JP2017509632 A JP 2017509632A JP 2017530947 A5 JP2017530947 A5 JP 2017530947A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- monocyclic
- independently selected
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 135
- 125000002950 monocyclic group Chemical group 0.000 claims description 64
- 125000003545 alkoxy group Chemical group 0.000 claims description 55
- 150000001875 compounds Chemical class 0.000 claims description 51
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 48
- 229910052736 halogen Inorganic materials 0.000 claims description 48
- 150000002367 halogens Chemical class 0.000 claims description 48
- 229910052739 hydrogen Inorganic materials 0.000 claims description 45
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 32
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 125000001424 substituent group Chemical group 0.000 claims description 32
- 229910052799 carbon Inorganic materials 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 24
- -1 wherein Chemical group 0.000 claims description 20
- 125000002619 bicyclic group Chemical group 0.000 claims description 16
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 16
- 235000010290 biphenyl Nutrition 0.000 claims description 16
- 239000004305 biphenyl Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 206010062016 Immunosuppression Diseases 0.000 claims description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
- 230000001506 immunosuppresive effect Effects 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 125000003566 oxetanyl group Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 8
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 230000001613 neoplastic effect Effects 0.000 claims description 5
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 208000026278 immune system disease Diseases 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 230000036210 malignancy Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 24
- 0 C[C@@](CC(NCc1cccc2c1cccc2)=O)NC([C@](CC(NC(C)(C)C)=O)*C(C(c1c[n]c2c1cccc2)=O)=O)=O Chemical compound C[C@@](CC(NCc1cccc2c1cccc2)=O)NC([C@](CC(NC(C)(C)C)=O)*C(C(c1c[n]c2c1cccc2)=O)=O)=O 0.000 description 10
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- AVQOGABHLMUNCV-UHFFFAOYSA-N CC(C(c1c[nH]c2c1cccc2)=O)=O Chemical compound CC(C(c1c[nH]c2c1cccc2)=O)=O AVQOGABHLMUNCV-UHFFFAOYSA-N 0.000 description 1
- VEXOILXWJURPSD-SSDOTTSWSA-N CC(C)(C)NC(C[C@@H](CC=O)N)=O Chemical compound CC(C)(C)NC(C[C@@H](CC=O)N)=O VEXOILXWJURPSD-SSDOTTSWSA-N 0.000 description 1
- UJIGIKQKDDJTJL-UHFFFAOYSA-N CC(c1c[s]c(C)n1)=O Chemical compound CC(c1c[s]c(C)n1)=O UJIGIKQKDDJTJL-UHFFFAOYSA-N 0.000 description 1
- DBZAKQWXICEWNW-UHFFFAOYSA-N CC(c1nccnc1)=O Chemical compound CC(c1nccnc1)=O DBZAKQWXICEWNW-UHFFFAOYSA-N 0.000 description 1
- JVSKTFUSPBYRGU-BKMJKUGQSA-N C[C@@H](C(NCc1c(cccc2)c2ccc1)=O)NC(C[C@H](CC(NC(C)(C)C)=O)NC(CCc1ccccc1)=O)=O Chemical compound C[C@@H](C(NCc1c(cccc2)c2ccc1)=O)NC(C[C@H](CC(NC(C)(C)C)=O)NC(CCc1ccccc1)=O)=O JVSKTFUSPBYRGU-BKMJKUGQSA-N 0.000 description 1
- ZZLJUYBFRITNFO-DHLKQENFSA-N C[C@@H](C(NCc1c(cccc2)c2ccc1)=O)NC(C[C@H](CCC(NC(C)(C)C)=O)NS(c1ccc(C)cc1)(=O)=O)=O Chemical compound C[C@@H](C(NCc1c(cccc2)c2ccc1)=O)NC(C[C@H](CCC(NC(C)(C)C)=O)NS(c1ccc(C)cc1)(=O)=O)=O ZZLJUYBFRITNFO-DHLKQENFSA-N 0.000 description 1
- QEBITORLVCJELG-JTQLQIEISA-N C[C@@H](C(NCc1cccc2c1cccc2)=O)N Chemical compound C[C@@H](C(NCc1cccc2c1cccc2)=O)N QEBITORLVCJELG-JTQLQIEISA-N 0.000 description 1
- IJINEWXLXZKFCF-WNCULLNHSA-N C[C@@H](CC(NCc1c(cccc2)c2ccc1)=O)NC(C[C@H](CC(NC(C)(C)C)=O)NC(CCc1ccccc1)=O)=O Chemical compound C[C@@H](CC(NCc1c(cccc2)c2ccc1)=O)NC(C[C@H](CC(NC(C)(C)C)=O)NC(CCc1ccccc1)=O)=O IJINEWXLXZKFCF-WNCULLNHSA-N 0.000 description 1
- UPGNHXSWIZSAJG-WIOPSUGQSA-N C[C@@H](CC(NCc1c(cccc2)c2ccc1)=O)NC(C[C@H](CC(NC(C)(C)C)=O)NS(c1ccc(C)cc1)(=O)=O)=O Chemical compound C[C@@H](CC(NCc1c(cccc2)c2ccc1)=O)NC(C[C@H](CC(NC(C)(C)C)=O)NS(c1ccc(C)cc1)(=O)=O)=O UPGNHXSWIZSAJG-WIOPSUGQSA-N 0.000 description 1
- NILMOKKCRYNYKK-CUNXSJBXSA-N C[C@@H](CC(NCc1c(cccc2)c2ccc1)=O)NC([C@H](CC(NC(C)(C)C)=O)NC(CCc1ccccc1)=O)=O Chemical compound C[C@@H](CC(NCc1c(cccc2)c2ccc1)=O)NC([C@H](CC(NC(C)(C)C)=O)NC(CCc1ccccc1)=O)=O NILMOKKCRYNYKK-CUNXSJBXSA-N 0.000 description 1
- PCIUTWMIYXBBAX-AVRDEDQJSA-N C[C@@H](CC(NCc1c(cccc2)c2ccc1)=O)NC([C@H](CC(NC(C)(C)C)=O)NC(OC(C)(C)C)=O)=O Chemical compound C[C@@H](CC(NCc1c(cccc2)c2ccc1)=O)NC([C@H](CC(NC(C)(C)C)=O)NC(OC(C)(C)C)=O)=O PCIUTWMIYXBBAX-AVRDEDQJSA-N 0.000 description 1
- CPIPXYUZLNDORA-JTSKRJEESA-N C[C@@H](CC(NCc1c(cccc2)c2ccc1)=O)NC([C@H](CC(NC(C)(C)C)=O)NS(C1CC1)(=O)=O)=O Chemical compound C[C@@H](CC(NCc1c(cccc2)c2ccc1)=O)NC([C@H](CC(NC(C)(C)C)=O)NS(C1CC1)(=O)=O)=O CPIPXYUZLNDORA-JTSKRJEESA-N 0.000 description 1
- GJFFOHRNWGHIHI-FIPFOOKPSA-N C[C@@H](CC(NCc1c(cccc2)c2ccc1)=O)NC([C@H](CCC(NC(C)(C)C)=O)NC(CCc1ccccc1)=O)=O Chemical compound C[C@@H](CC(NCc1c(cccc2)c2ccc1)=O)NC([C@H](CCC(NC(C)(C)C)=O)NC(CCc1ccccc1)=O)=O GJFFOHRNWGHIHI-FIPFOOKPSA-N 0.000 description 1
- VITDJXMDPKLTET-LVXARBLLSA-N C[C@@H](CC(NCc1cccc2c1cccc2)=O)NC([C@H](CC(NC(C)(C)C)=O)NS(c1ccc(C)cc1)(=O)=O)=O Chemical compound C[C@@H](CC(NCc1cccc2c1cccc2)=O)NC([C@H](CC(NC(C)(C)C)=O)NS(c1ccc(C)cc1)(=O)=O)=O VITDJXMDPKLTET-LVXARBLLSA-N 0.000 description 1
- COWKEGNUMOGJEA-AWEZNQCLSA-N C[C@@H](CC(NCc1cccc2ccccc12)=O)NC(OC(C)(C)C)=O Chemical compound C[C@@H](CC(NCc1cccc2ccccc12)=O)NC(OC(C)(C)C)=O COWKEGNUMOGJEA-AWEZNQCLSA-N 0.000 description 1
- FYSCTGDLZFPNTI-UHFFFAOYSA-N Cc(cc1)ccc1[S+](=O)=O Chemical compound Cc(cc1)ccc1[S+](=O)=O FYSCTGDLZFPNTI-UHFFFAOYSA-N 0.000 description 1
- WMXFNCKPYCAIQW-UHFFFAOYSA-N Cc1cccc(OC)c1OC Chemical compound Cc1cccc(OC)c1OC WMXFNCKPYCAIQW-UHFFFAOYSA-N 0.000 description 1
- DLTHEPWEENQLKV-UHFFFAOYSA-N Cc1cnc2[n]1cccc2 Chemical compound Cc1cnc2[n]1cccc2 DLTHEPWEENQLKV-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- VBKAPLYISDSUCE-UHFFFAOYSA-N Ic1c2[nH]ccc2ccc1 Chemical compound Ic1c2[nH]ccc2ccc1 VBKAPLYISDSUCE-UHFFFAOYSA-N 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- LILSBXJJIIFDGR-UHFFFAOYSA-N Nc1c2NCCCc2ccc1 Chemical compound Nc1c2NCCCc2ccc1 LILSBXJJIIFDGR-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462038636P | 2014-08-18 | 2014-08-18 | |
| US62/038,636 | 2014-08-18 | ||
| PCT/US2015/044876 WO2016028571A2 (en) | 2014-08-18 | 2015-08-12 | Dipeptidomimetics as inhibitors of human immunoproteasomes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530947A JP2017530947A (ja) | 2017-10-19 |
| JP2017530947A5 true JP2017530947A5 (enExample) | 2018-09-13 |
| JP6758282B2 JP6758282B2 (ja) | 2020-09-23 |
Family
ID=55351371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017509632A Active JP6758282B2 (ja) | 2014-08-18 | 2015-08-12 | ヒト免疫プロテアソーム阻害剤としてのジペプチド模倣薬 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US11202817B2 (enExample) |
| EP (1) | EP3193904B1 (enExample) |
| JP (1) | JP6758282B2 (enExample) |
| CN (2) | CN107073069B (enExample) |
| WO (1) | WO2016028571A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2748434T3 (es) | 2014-01-10 | 2020-03-16 | Univ Cornell | Dipéptidos como inhibidores de inmunoproteasomas humanos |
| US11202817B2 (en) * | 2014-08-18 | 2021-12-21 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
| EP4006012A1 (en) | 2015-10-15 | 2022-06-01 | Cornell University | Proteasome inhibitors and uses thereof |
| WO2019075252A1 (en) | 2017-10-11 | 2019-04-18 | Cornell University | PEPTIDOMIMETIC INHIBITORS OF PROTEASOME |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW223629B (enExample) | 1992-03-06 | 1994-05-11 | Hoffmann La Roche | |
| US7001921B1 (en) | 1995-01-23 | 2006-02-21 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
| AR011515A1 (es) | 1996-12-25 | 2000-08-30 | Agrogene Ltd | Derivado del acido aminobutirico para la proteccion de plantas de enfermedades fungosas y un metodo para proteger un cultivo contra enfermedadesfungosas por ejemplo tomates y papas contra el tizon tardio o temprano, cereales contra el mildiu polvoroso, y pepino, vides, melones contra el mildiu |
| CA2423868C (en) | 2000-09-29 | 2011-06-07 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| US7244743B2 (en) | 2002-06-05 | 2007-07-17 | Solvay Pharmaceuticals Gmbh | Non-peptidic BRS-3 agonists |
| AU2003262642B2 (en) * | 2002-08-14 | 2010-06-17 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| CN100367949C (zh) | 2002-09-13 | 2008-02-13 | 有限会社绪方研究 | 黑色素消除制剂 |
| TWI334868B (en) * | 2003-06-03 | 2010-12-21 | Nippon Kayaku Kk | [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof |
| AR050258A1 (es) | 2004-07-21 | 2006-10-11 | Mitsui Chemicals Inc | Derivado de diamina, proceso de la preparacion de este, y fungicida que contiene el derivado de diamina como ingrediente activo |
| TW200621223A (en) | 2004-09-07 | 2006-07-01 | Smithkline Beecham Corp | Acyclic 1,3-diamines and uses therefor |
| WO2006065826A2 (en) * | 2004-12-15 | 2006-06-22 | Merck & Co., Inc. | Process to chiral beta amino acid derivatives by asymmetric hydrogenation |
| US7589066B2 (en) | 2005-03-11 | 2009-09-15 | The University Of North Carolina At Chapel Hill | Potent and specific immunoproteasome inhibitors |
| JP2006298785A (ja) | 2005-04-18 | 2006-11-02 | Mitsui Chemicals Inc | ジアミン誘導体、その製造方法およびそれらを有効成分とする殺菌剤 |
| US20090227601A1 (en) | 2005-12-07 | 2009-09-10 | Amgen Inc. | Bradykinin 1 Receptor Antagonists |
| WO2007083394A1 (ja) | 2006-01-19 | 2007-07-26 | Mitsui Chemicals, Inc. | ジアミン誘導体を含む有害生物防除組成物 |
| NZ597545A (en) | 2006-06-19 | 2013-07-26 | Proteolix Inc | Peptide epoxyketones for proteasome inhibition |
| DE102007025718A1 (de) * | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
| US8183235B2 (en) | 2007-09-11 | 2012-05-22 | Tokyo University Of Science Educational Foundation Administrative Organization | Dihydronaphthalene compound and use thereof |
| EP2212334B1 (en) | 2007-10-16 | 2012-08-15 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| WO2010038200A1 (en) | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
| AU2011223795B2 (en) | 2010-03-01 | 2015-11-05 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| AU2011235227B2 (en) | 2010-03-31 | 2016-09-08 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| EP2487152A1 (en) | 2010-11-17 | 2012-08-15 | UCB Pharma GmbH | Process for the preparation of Lacosamide including resolution of O-methyl-DL-serine |
| CA2828456C (en) | 2011-03-03 | 2021-05-04 | Zalicus Pharmaceuticals Ltd. | N-benzl-amino-carboxamide inhibitors of the sodium channel |
| EP2949344A3 (en) | 2011-03-18 | 2016-01-13 | Catabasis Pharmaceuticals, Inc. | Use of intracellular enzymes for the release of covalently linked bioactives |
| CN102807601B (zh) | 2011-06-03 | 2014-02-26 | 首都医科大学 | 氨基酰-色氨酰-5-甲氧色胺及其制备方法和应用 |
| GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| SG10201605152SA (en) | 2011-12-22 | 2016-08-30 | Ares Trading Sa | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
| JP2014091731A (ja) | 2012-11-06 | 2014-05-19 | Kobe Gakuin | 新規ソマトスタチン由来ペプチド化合物並びに該化合物を含むｄｎａポリメラーゼ阻害剤、抗癌剤及びアポトーシス誘導剤。 |
| NZ708175A (en) | 2012-12-21 | 2020-06-26 | Hoffmann La Roche | Peptides as oxytocin agonists |
| WO2015076359A1 (ja) | 2013-11-21 | 2015-05-28 | 国立大学法人北海道大学 | プロテアソーム阻害性化合物 |
| ES2748434T3 (es) | 2014-01-10 | 2020-03-16 | Univ Cornell | Dipéptidos como inhibidores de inmunoproteasomas humanos |
| US11202817B2 (en) * | 2014-08-18 | 2021-12-21 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
| EP4006012A1 (en) | 2015-10-15 | 2022-06-01 | Cornell University | Proteasome inhibitors and uses thereof |
| WO2019075252A1 (en) | 2017-10-11 | 2019-04-18 | Cornell University | PEPTIDOMIMETIC INHIBITORS OF PROTEASOME |
-
2015
- 2015-08-12 US US15/504,951 patent/US11202817B2/en active Active
- 2015-08-12 CN CN201580056519.4A patent/CN107073069B/zh active Active
- 2015-08-12 WO PCT/US2015/044876 patent/WO2016028571A2/en not_active Ceased
- 2015-08-12 CN CN202210151955.1A patent/CN114796207A/zh active Pending
- 2015-08-12 EP EP15834073.7A patent/EP3193904B1/en active Active
- 2015-08-12 JP JP2017509632A patent/JP6758282B2/ja active Active
-
2021
- 2021-11-22 US US17/532,285 patent/US12016896B2/en active Active
-
2024
- 2024-05-03 US US18/655,057 patent/US20250114428A1/en active Pending